corresponding antagonist c(RGD7) derived from the isomeric 4-amino-CPA. Both compounds were also nanomolar ligands of the α5β1 integrin (expressed in human erythroleukemia cell line K562). These results suggest that the CPA-derived templates are suitable for the preparation of dual αvβ3 and α5β1 ligands to suppress integrin-mediated events as well as for targeted drug delivery in cancer therapy.
使用在羧基和
氨基之间具有顺式相对立体
化学的4-
氨基和5-
氨基-
环丙烷哌啶酸(CPA)作为模板,以制备含有RGD序列(可能是整联蛋白结合剂)的环状拟肽。拟肽C(RGD8)建立在5-
氨基CPA显示的抑制活性(IC 50 = 2.4 nm)的朝向α v β 3整联蛋白受体(在M21人黑素瘤
细胞系中表达)相比的最有效拮抗剂的迄今已报道,其活性是衍生自4-
氨基-CPA异构体的相应拮抗剂c(RGD7)的十倍。这两种化合物也作为α纳摩尔
配体5 β1整联蛋白(在人类红白血病
细胞系K562中表达)。这些结果表明,该CPA衍生的模板是适合于双制备α v β 3和α 5 β 1的
配体,抑制整合素介导的事件,以及用于在癌症治疗中靶向药物递送。